Medicare_Carriers_Manual / 2049 / 2049.4_Reasonableness_and_Necessity.--

Why This Topic Matters

It helps readers understand the scope of Medicare coverage review for medications and biologics, including how FDA approval status, compendia support, and selected vaccine categories affect payment decisions. It is useful for organizations that need to align billing and medical-necessity review processes with Medicare policy.

Article Sections

1. General Reasonableness and Necessity Standard

   Introduces the overall Medicare standard for drugs and biologicals and the general conditions that must be met for payment consideration. It also addresses how FDA approval status affects coverage review.

2. FDA Approval Evidence and Unlabeled Use

   Describes acceptable ways to document FDA approval and discusses coverage review for unlabeled drug use. It also outlines broader factors used when evaluating medically accepted use.

3. Guidelines for Noncovered Medication Situations

   Presents general categories of medication situations that may not meet Medicare coverage standards. The section focuses on broad screening categories and payment implications.

4. Antigens

   Discusses Medicare payment conditions for certain patient-specific antigens and the concept of a reasonable supply. It also notes supervision and preparation requirements.

5. Immunizations

   Provides general vaccine coverage context and identifies selected vaccine categories treated differently under Medicare. The section also distinguishes preventive and exposure-related immunization coverage.

6. Pneumococcal Pneumonia Vaccinations

   Summarizes Medicare Part B coverage guidance for pneumococcal vaccination services, including administration and revaccination considerations. It also references timing and beneficiary access details.

7. Hepatitis B Vaccine

   Outlines Medicare Part B coverage for hepatitis B vaccination and administration for beneficiaries in identified risk groups. It also addresses related provider settings and laboratory-status considerations.

8. Influenza Virus Vaccine

   Describes Medicare Part B coverage for influenza vaccination and administration services. The section notes general seasonal use and access considerations.

9. Unlabeled Use For Anti-Cancer Drugs

   Explains the framework for evaluating certain anti-cancer drug uses that are not on approved labeling. It covers recognized sources consulted for medically accepted use determinations.

10. Compendia and Peer-Reviewed Literature

    Discusses the reference sources used to evaluate anti-cancer drug use and the role of peer-reviewed literature. It also describes the types of publications and evidence considerations involved.

11. Less Than Effective Drug

    Addresses drug products identified as lacking substantial evidence of effectiveness and the implications for payment. It includes general treatment of related products.

12. Denial of Medicare Payment for Compounded Drugs Produced in Violation of Federal Food, Drug, and Cosmetic Act

    Discusses Medicare handling of compounded drugs when FDA determines production violates federal law. It also addresses related administrative notification and payment actions.